OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Celldex Therapeutics OCF Yield % Related Terms
Celldex Therapeutics OCF Yield % Historical Data
* Premium members only.
The historical data trend for Celldex Therapeutics's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Celldex Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celldex Therapeutics OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Celldex Therapeutics's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celldex Therapeutics (CLDX) has a OCF Yield % of -8.03 as of Jun. 27, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Celldex Therapeutics and its competitors. According to the industry distribution chart, Celldex Therapeutics ranks #706 out of 1419 companies in the Biotechnology industry, placing it in the top 49.8%.
Is Celldex Therapeutics' OCF Yield % too high?
Celldex Therapeutics' current OCF Yield % is -8.03. Based on the distribution chart, Celldex Therapeutics ranks #706 out of 1419 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Celldex Therapeutics has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celldex Therapeutics' OCF Yield % compare to IMNM and ELVN?
According to the Biotechnology industry distribution chart, Celldex Therapeutics ranks #706 out of 1419 companies for OCF Yield %. This puts Celldex Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Celldex Therapeutics and its competitors. Celldex Therapeutics's current OCF Yield % is -8.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celldex Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Celldex Therapeutics (CLDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.88, compared to a current price of $35.23 — trading 412.1% above its estimated fair value. The current OCF Yield % is -8.03. Celldex Therapeutics' overall GF Score™ is 57/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Celldex Therapeutics (CLDX), the current OCF Yield % is -8.03 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celldex Therapeutics (CLDX) Overvalued in 2026?
Based on GuruFocus' analysis, Celldex Therapeutics stock appears to be overvalued.
The current stock price of $35.23 is trading 412.1% above its estimated GF Value™ of $6.88.
GuruFocus considers Celldex Therapeutics to be Significantly Overvalued.
Key valuation signals for CLDX:
OCF Yield %: -8.03
GF Value™: $6.88 vs. price of $35.23 (412.1% above fair value)
No single metric tells the full story. See the CLDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
57GF Score
Get the complete analysis for CLDX
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLDX has been successfully added to your 
